SciMar Ltd. was founded in 2009 to advance the pioneering medical research of Dr. Wayne Lautt and his team as they work to unveil hepatic insulin-sensitizing substance (HISS) as the foundation of a new paradigm in the prevention and treatment of type 2 diabetes.

For Investors

SciMar is opening a Series A round to take clinical testing and product development to the next level.

Product Pipeline

SciMar is developing four distinct products to measure and protect metabolic health.

Wellness Transformation Network (WTN)

The network brings together like-minded businesses and organizations to promote better health.

The Science

The hormone HISS was first discovered in 1996. As knowledge of its role grows, so will the impact on human health.